News | May 31, 2023
Synexa Joins CEPI in advancing global epidemic preparedness and response
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
Allianz is ISO 9001:2015 certified and INVIMA certified for storage, sampling, dispensation, and distribution of APIs to the Colombian market
Subscribe To Our Newsletter & Stay Updated
